Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares on May 22 at an average price of $567.74, generating about $5.39 million in proceeds. After the sale, she still held 40,513 shares, and the transaction reduced her position by 19%.
- UTHR shares were up 1.8% and opened at $578.43, near the stock’s 52-week high of $609.35. The company currently has a market cap of $24.55 billion and a beta of 0.60.
- Recent earnings missed expectations, with United Therapeutics reporting $5.82 EPS versus the $7.00 consensus and revenue of $781.5 million versus forecasts of $797.4 million. Despite the miss, analysts remain broadly positive, with a consensus rating of “Moderate Buy” and a target price of $619.42.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $567.74, for a total value of $5,393,530.00. Following the sale, the chief executive officer owned 40,513 shares of the company's stock, valued at approximately $23,000,850.62. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
United Therapeutics Stock Up 1.8%
UTHR stock opened at $578.43 on Wednesday. The company has a market cap of $24.55 billion, a P/E ratio of 21.35, a PEG ratio of 1.84 and a beta of 0.60. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The business has a fifty day moving average of $564.81 and a 200-day moving average of $513.93.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company's quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $6.63 earnings per share. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.
Analyst Ratings Changes
UTHR has been the subject of a number of recent research reports. UBS Group boosted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research note on Thursday, March 5th. Cantor Fitzgerald boosted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Raymond James Financial began coverage on United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price objective for the company. Royal Bank Of Canada dropped their price objective on United Therapeutics from $707.00 to $701.00 and set an "outperform" rating for the company in a report on Thursday, May 7th. Finally, HC Wainwright upped their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $619.42.
View Our Latest Stock Analysis on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
Hedge funds have recently bought and sold shares of the company. Arjuna Capital raised its position in United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after purchasing an additional 18 shares during the last quarter. Clearstead Advisors LLC raised its position in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 23 shares during the last quarter. Sage Rhino Capital LLC raised its position in United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC raised its position in United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock valued at $276,000 after purchasing an additional 24 shares during the last quarter. Finally, Meeder Advisory Services Inc. raised its stake in shares of United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after acquiring an additional 26 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
